Ferric carboxymaltose for the treatment of iron-deficiency anemia

Bibliography

• Ludwig H, Van Belle S, Barrett-Lee P, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-307
   PubMed Web of Science ®Google Scholar
• Furst DE, Chang H, Greenberg JD, Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol 2009;27:560-6
   PubMed Web of Science ®Google Scholar
• Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet 2010;282:577-80
   PubMed Web of Science ®Google Scholar
• Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006;73:289-97
   PubMed Web of Science ®Google Scholar
• He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009;15:123-30
   PubMedGoogle Scholar
• Wu WC, Schifftner TL, Henderson WG, Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007;297:2481-8
   PubMed Web of Science ®Google Scholar
• Vincent JL, Baron JF, Reinhart K, Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507
   PubMed Web of Science ®Google Scholar
• Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011;64:281-6
   PubMed Web of Science ®Google Scholar
• Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: Iron deficiency and iron overload. J Clin Pathol 2011;64:287-96
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-33
   PubMed Web of Science ®Google Scholar
• Beris P, Munoz M, Garcia-Erce JA, Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008;100:599-604
   PubMed Web of Science ®Google Scholar
• Gasche C, Berstad A, Befrits R, Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53
   PubMed Web of Science ®Google Scholar
• KDOQI. Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
   PubMed Web of Science ®Google Scholar
• Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944-82
   PubMed Web of Science ®Google Scholar
• Breymann C, Bian XM, Blanco-Capito LR, Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med 2011;39:113-21
   PubMed Web of Science ®Google Scholar
• Munoz M, Breymann C, Garcia-Erce JA, Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008;94:172-83
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-47
   PubMed Web of Science ®Google Scholar
• Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-8
   PubMed Web of Science ®Google Scholar
• Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-8
   PubMed Web of Science ®Google Scholar
• Lu M, Suh KR, Lee H-Z, FDA review of ferumoxytol (Feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease. Am J Hematol 2010;85:315-19
   PubMed Web of Science ®Google Scholar
• Jahn MR, Andreasen HB, Futterer S, A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-91
   PubMed Web of Science ®Google Scholar
• Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42:1439-52
   PubMed Web of Science ®Google Scholar
• Funk F, Ryle P, Canclini C, The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010;60:345-53
   PubMed Web of Science ®Google Scholar
• Geisser P, Banke-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung 2010;60:362-72
   PubMed Web of Science ®Google Scholar
• Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung 2010;60:373-85
   PubMed Web of Science ®Google Scholar
• Beshara S, Sorensen J, Lubberink M, Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003;120:853-9
   PubMed Web of Science ®Google Scholar
• Crichton RR, Danielson BG, Geisser P. Iron Therapy with Special Emphasis on Intravenous Administration. 4th edition. IMPG; London, Boston: 2008
   Google Scholar
• Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008;101:67-73
   PubMed Web of Science ®Google Scholar
• Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010;25:2722-30
   PubMed Web of Science ®Google Scholar
• Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int 2010;14:47-54
   PubMed Web of Science ®Google Scholar
• Qunibi WJ, Martinez C, Smith M, A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron fro treatment of iron deficiency anemia of non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2011;26:1599-607
   PubMed Web of Science ®Google Scholar
• Moore RA, Gaskell H, Rose P, Allen J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011;11:4
   Google Scholar
• Schaefer RM, Khasabov NN, Todorov NG, Evenepoel P. Intravenous ferric carboxymaltose or iron sucrose to treat iron deficiency anaemia in haemodialysis patients. Poster presented at the XLV ERA-EDTA Congress; 10 – 1 May 2008
   Google Scholar
• Clinical Study Report CARS 1. Vifor Pharmaceuticals. Data on file. A pilot randomised double-blind Controlled phase III study to compare the efficacy and safety of Ferinject® and Venofer® versus standard therapy in patients with chronic heart failure, renal failure and iron deficiency (CARS I). 2008
   Google Scholar
• Anker SD, Comin Colet J, Filippatos G, the FAIR-HF Trial Investigators. Stockholm, Sweden. Poster MP375. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:3436-48
   Google Scholar
• Van Wyck DB, Martens MG, Seid MH, Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomised controlled trial. Obstet Gynecol 2007;110:267-78
   PubMed Web of Science ®Google Scholar
• Seid MH, Derman RJ, Baker JB, Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008;199:435-7
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Mangione A, Morrison J, Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-28
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Stoinov S, Simanenkov V, A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92
   PubMed Web of Science ®Google Scholar
• Evstatiev R, Marteau P, Iqbal T, FERGIcor, randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease disease. Gastroenterology 2011;141:846-53
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Teischinger L, Dejaco C, Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009;104:1460-7
   PubMed Web of Science ®Google Scholar
• Bisbe E, Garcia-Erce JA, Diez-Lobo AI, Munoz M; Anaemia Working Group Espana. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011;107:477-8
   PubMed Web of Science ®Google Scholar
• Munoz M, Naveira E, Seara J, Postoperative iron after lower limb arthroplasty: a comparative study of the effects of 300 vs. 600 mg IV iron administration on transfusion requirements. Transfus Altern Transfus Med 2011;12:34-5
   Google Scholar
• Hildebrandt P, Bruun NE, Nielsen OW, Intravenous iron supplementation with Monofer improves quality of life assessments in patients with chronic heart failure [abstract]. Transfus Altern Transfus Med 2010;11(Suppl 2):35
   Google Scholar
• Wikstrom B, Bhandari S, Barany P, Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011;24:589-96
   PubMed Web of Science ®Google Scholar
• Auerbach M, Pappadakis JA, Bahrain H, Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011;86:860-2
   PubMed Web of Science ®Google Scholar
• Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011;4:399-406
   PubMed Web of Science ®Google Scholar
• Food and drug administration center for drug evaluation and research. Summary minutes of the drug safety and risk management advisory committee, February 1, 2008. Available from: http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4337m1-Final.pdf
   Google Scholar
• Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010;90:804-5
   PubMed Web of Science ®Google Scholar
• AMCP Formulary Submission Dossier: FerahemeTM. A Phase III Study of The Safety and Efficacy of Feraheme (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis. AMAG Pharmaceuticals, Inc; Lexington, MA: 2009
   Google Scholar
• Spinowitz BS, Kausz AT, Baptista J, Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605
   PubMed Web of Science ®Google Scholar
• Singh A, Patel T, Hertel J, Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008;52:907-15
   PubMed Web of Science ®Google Scholar
• Provenzano R, Schiller B, Rao M, Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-93
   PubMed Web of Science ®Google Scholar
• Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 2012;69:310-20
   PubMed Web of Science ®Google Scholar
• Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohn Colitis 2010;4:427-30
   PubMed Web of Science ®Google Scholar
• Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag 2011;7:501-9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-82
   PubMed Web of Science ®Google Scholar